KR100282575B1 - 염증성 피부병치료용 약제학적 조성물 - Google Patents

염증성 피부병치료용 약제학적 조성물 Download PDF

Info

Publication number
KR100282575B1
KR100282575B1 KR1019940702690A KR19940702690A KR100282575B1 KR 100282575 B1 KR100282575 B1 KR 100282575B1 KR 1019940702690 A KR1019940702690 A KR 1019940702690A KR 19940702690 A KR19940702690 A KR 19940702690A KR 100282575 B1 KR100282575 B1 KR 100282575B1
Authority
KR
South Korea
Prior art keywords
acid
tetramethyl
tetrahydro
naphthalenyl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019940702690A
Other languages
English (en)
Korean (ko)
Other versions
KR950700069A (ko
Inventor
알버트엠.클릭만
Original Assignee
알버트엠.클릭만
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알버트엠.클릭만 filed Critical 알버트엠.클릭만
Publication of KR950700069A publication Critical patent/KR950700069A/ko
Application granted granted Critical
Publication of KR100282575B1 publication Critical patent/KR100282575B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019940702690A 1992-02-07 1993-01-29 염증성 피부병치료용 약제학적 조성물 Expired - Fee Related KR100282575B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83282892A 1992-02-07 1992-02-07
US7/832.828 1992-02-07
US07/832,828 1992-02-07
PCT/US1993/001043 WO1993015740A1 (en) 1992-02-07 1993-01-29 Methods of treating inflammatory dermatoses

Publications (2)

Publication Number Publication Date
KR950700069A KR950700069A (ko) 1995-01-16
KR100282575B1 true KR100282575B1 (ko) 2001-02-15

Family

ID=25262717

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702690A Expired - Fee Related KR100282575B1 (ko) 1992-02-07 1993-01-29 염증성 피부병치료용 약제학적 조성물

Country Status (12)

Country Link
US (1) US5998395A (enrdf_load_stackoverflow)
EP (1) EP0625045A4 (enrdf_load_stackoverflow)
JP (1) JP2927961B2 (enrdf_load_stackoverflow)
KR (1) KR100282575B1 (enrdf_load_stackoverflow)
AU (1) AU667519B2 (enrdf_load_stackoverflow)
CA (1) CA2129114A1 (enrdf_load_stackoverflow)
CZ (1) CZ188394A3 (enrdf_load_stackoverflow)
FI (1) FI943625L (enrdf_load_stackoverflow)
NO (1) NO942913L (enrdf_load_stackoverflow)
NZ (1) NZ249379A (enrdf_load_stackoverflow)
WO (1) WO1993015740A1 (enrdf_load_stackoverflow)
ZA (1) ZA93811B (enrdf_load_stackoverflow)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE202935T1 (de) * 1992-09-11 2001-07-15 Sandra Brown Verfahren zur behandlung von haarausfall
US6344448B1 (en) 1992-09-11 2002-02-05 Stb Family Limited Partnership Composition for the treatment of hair loss
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
WO1996034601A1 (en) * 1995-05-05 1996-11-07 Braiman Mark S Treatment of psoriasis with 11-cis-retinoic acid
US6008254A (en) * 1997-05-09 1999-12-28 Kligman; Douglas E. Method of treating skin disorders with high-strength tretinoin
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
US6355669B1 (en) * 1997-10-22 2002-03-12 Eisai Co., Ltd. Retinoic acid agonists as preventive and therapeutic agents for nephritis
FR2761600B1 (fr) * 1998-06-19 2000-03-31 Oreal Composition moussante pour le lavage et le traitement des cheveux et/ou du cuir chevelu a base d'un principe actif, d'un tensioactif anionique, d'un tensioactif amphotere et d'un agent propenetrant
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
FR2804323B1 (fr) * 2000-01-31 2006-07-07 Galderma Res & Dev Utilisation de composes de type retinoides en tant qu'agents anti-bacteriens
US20050003023A1 (en) * 2002-06-28 2005-01-06 Meisner Lorraine Faxon Topical composition for the treatment of psoriasis and related skin disorders
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
DE60135108D1 (de) * 2000-05-09 2008-09-11 Kaneka Corp Dermale zusammenstellungen die als wirkstoff coenzym q enthalten
AU2001290816A1 (en) 2000-09-13 2002-03-26 Bristol-Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
KR20020027198A (ko) * 2000-10-02 2002-04-13 차알스 제이. 메츠 염증과 홍반의 완화방법
FR2823117A1 (fr) * 2000-11-14 2002-10-11 Pharmascience Lab Composition pharmaceutique ou cosmetique ainsi que l'utilisation d'au moins un compose actif pour inhiber la migration des cellules de langerhans
WO2002071025A2 (en) * 2001-03-02 2002-09-12 Spectra Systems Corporation Combinatorial chemistry and compound identification system
ES2188426B1 (es) * 2001-12-12 2004-11-16 Rosalia Pidal Fernandez Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
US20030199488A1 (en) * 2002-04-23 2003-10-23 Trotta Gina M. Treatment of hyperproliferative disorders/inflammatory dermatoses
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
US20040171561A1 (en) * 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
CA2528776A1 (en) * 2002-10-24 2004-05-06 G & R Pharmaceuticals, Llc Antifungal formulations
US20050095215A1 (en) * 2003-11-03 2005-05-05 Popp Karl F. Antimicrobial shampoo compositions
BRPI0416812A (pt) * 2003-11-21 2007-03-06 Combinatorx Inc métodos e reagentes para o tratamento de desordens inflamatórias
AU2005213895A1 (en) * 2004-02-19 2005-09-01 Chemaphor Inc. Topical formulations for the treatment of skin conditions
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
SG155959A1 (en) 2004-09-28 2009-10-29 Chemaphor Inc Compositions and methods for promoting weight gain and feed conversion
US20070009607A1 (en) * 2005-07-11 2007-01-11 George Jones Antibacterial/anti-infalmmatory composition and method
US10449247B2 (en) 2007-10-26 2019-10-22 Avivagen Inc. Compositions and methods for enhancing immune response
ES2327201B1 (es) 2008-04-23 2010-07-23 Ignacio Umbert Millet Composicion farmaceutica personalizada para el rejuvenecimiento de la piel que contiene acido retinoico.
WO2010124391A1 (en) 2009-04-30 2010-11-04 Chemaphor Inc. Methods and compositions for improving the health of animals
WO2011050102A1 (en) 2009-10-20 2011-04-28 Discovery Partners, LLC Dermatologic and cosmetic compositions
ES2378028B1 (es) 2012-02-22 2013-02-18 Ignacio Umbert Millet Composición cosmética para el rejuvenecimiento de la piel y procedimiento y usos correspondientes
MX392053B (es) * 2017-09-28 2025-03-21 Johnson & Johnson Consumer Inc Composiciones cosmeticas y metodo para tratar la piel
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889847A (en) * 1986-11-03 1989-12-26 Ortho Pharmaceutical Corporation Prevention of glucocorticoid-induced skin atrophy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3729568A (en) * 1969-09-23 1973-04-24 Johnson & Johnson Acne treatment
US4126693A (en) * 1975-11-03 1978-11-21 Johnson & Johnson Retinoic acid derivatives in the treatment of acne
ZA77678B (en) * 1977-02-07 1978-09-27 S Fourie Pharmaceutical composition and use thereof
US4487782A (en) * 1982-03-26 1984-12-11 Ortho Pharmaceutical Corporation Topical treatment of non-inflammatory acne
US5019569A (en) * 1986-11-03 1991-05-28 Ortho Pharmaceutical Corporation Reversal of glucocorticoid-induced skin atrophy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889847A (en) * 1986-11-03 1989-12-26 Ortho Pharmaceutical Corporation Prevention of glucocorticoid-induced skin atrophy

Also Published As

Publication number Publication date
ZA93811B (en) 1993-09-10
NO942913D0 (enrdf_load_stackoverflow) 1994-08-05
JPH07505617A (ja) 1995-06-22
FI943625A7 (fi) 1994-08-04
AU3585493A (en) 1993-09-03
AU667519B2 (en) 1996-03-28
FI943625A0 (fi) 1994-08-04
CA2129114A1 (en) 1993-08-19
WO1993015740A1 (en) 1993-08-19
NO942913L (no) 1994-10-05
JP2927961B2 (ja) 1999-07-28
US5998395A (en) 1999-12-07
EP0625045A1 (en) 1994-11-23
NZ249379A (en) 1998-07-28
CZ188394A3 (en) 1996-02-14
EP0625045A4 (en) 1995-01-18
FI943625L (fi) 1994-08-04
KR950700069A (ko) 1995-01-16

Similar Documents

Publication Publication Date Title
KR100282575B1 (ko) 염증성 피부병치료용 약제학적 조성물
US4889847A (en) Prevention of glucocorticoid-induced skin atrophy
US7939516B2 (en) Topical skin care composition
US8945636B2 (en) Stabilized formulation comprising omega-3 fatty acids and use of the fatty acids for skin care and/or wound care
US5019569A (en) Reversal of glucocorticoid-induced skin atrophy
JP5194383B2 (ja) ニキビ治療剤
JPH0859463A (ja) クマリンを含む調製物および薬剤および美容分野におけるそれらの使用
US20150094370A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
Bukvic Mokos et al. Perioral dermatitis: Still a therapeutic challenge
Roeder et al. Tazarotene: therapeutic strategies in the treatment of psoriasis, acne and photoaging
EP3795163A1 (en) A topical plant extract formulation comprising urtica dioica and vitamin a
KR20220079894A (ko) 외피계 상처를 치료하기 위한 국소 제형 및 점적제, 키트 및 방법, 및 이의 용도
JP3839502B2 (ja) 湿疹・皮膚炎群治療剤
Hui et al. 1 Topical retinoids
Rusdy et al. Adjuvant therapies of acne: review of literatures
NZ286443A (en) Treatment of inflammatory dermatoses other than psoriasis using a retinoid and a corticosteroid
WO2019175902A1 (en) A topical preparation for various skin ailments
WO2024263134A1 (en) Safe and effective drug formulation used for the treatment of psoriasis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20031130

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20031130